🔗 Share this article Individuals Coming Off Anti-Obesity Injections Put On Weight Four Times Faster Than Those on Conventional Diets Weight management involves ongoing approaches. A recent study suggests that individuals who stop using new GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight far faster than those who halt conventional lifestyle plans. Research printed in a prominent medical journal points out that while obese individuals often shed a large proportion of their total mass while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month upon discontinuation. "People buying such drugs need to be informed of the danger of fast weight regain when the medication concludes," warns lead investigator Dr. Susan Jebb. Such speed of regain implies a reversion to original mass in about 18 months. Weighing Therapies The study, which looked at dozens of trials involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with other pills. Researchers point out that individuals who lose weight through diet and exercise generally experience a slower weight regain—perhaps 100 grams monthly—post-intervention. Explaining the Fast Regain Nutrition scientists propose the way of the drugs is key to understanding the amplified rebound. These medications copy a body's own chemical called GLP-1, which moderates hunger. "Long-term administration of GLP-1 concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher. "Withdrawal of this hormone supplement results in hunger is no longer kept in check, making binge eating far more likely." A Chronic Issue? The NHS recommend the injections for individuals with weight-linked health risks, alongside recommended lifestyle changes. A number of clinicians argue that, considering the significant potential of relapse, the treatment is often ongoing. This perspective is reinforced by drug manufacturers, who say that the findings "underscore the long-term character of obesity," similar to managing conditions like high blood pressure. Patient Testimonies Individuals who have stopped the jabs describe a sudden resurgence of cravings. "It felt as if something flipping and I was suddenly ravenous," recalled a patient. This challenge is compounded if users have not established lasting lifestyle or habit modifications during treatment. Growing Interest Survey data show that millions of adults in the UK have used these injections in the past year, with interest remaining high. Use is more common among females than males. The 40s and 50s demographic shows the greatest level of interest. Many obtain the medications through private healthcare rather than the NHS. Finally, clinicians emphasize that while these medications are powerful agents for weight loss, they are not a permanent cure and lasting health benefits hinges on combined behavioural support.
Weight management involves ongoing approaches. A recent study suggests that individuals who stop using new GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight far faster than those who halt conventional lifestyle plans. Research printed in a prominent medical journal points out that while obese individuals often shed a large proportion of their total mass while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month upon discontinuation. "People buying such drugs need to be informed of the danger of fast weight regain when the medication concludes," warns lead investigator Dr. Susan Jebb. Such speed of regain implies a reversion to original mass in about 18 months. Weighing Therapies The study, which looked at dozens of trials involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with other pills. Researchers point out that individuals who lose weight through diet and exercise generally experience a slower weight regain—perhaps 100 grams monthly—post-intervention. Explaining the Fast Regain Nutrition scientists propose the way of the drugs is key to understanding the amplified rebound. These medications copy a body's own chemical called GLP-1, which moderates hunger. "Long-term administration of GLP-1 concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher. "Withdrawal of this hormone supplement results in hunger is no longer kept in check, making binge eating far more likely." A Chronic Issue? The NHS recommend the injections for individuals with weight-linked health risks, alongside recommended lifestyle changes. A number of clinicians argue that, considering the significant potential of relapse, the treatment is often ongoing. This perspective is reinforced by drug manufacturers, who say that the findings "underscore the long-term character of obesity," similar to managing conditions like high blood pressure. Patient Testimonies Individuals who have stopped the jabs describe a sudden resurgence of cravings. "It felt as if something flipping and I was suddenly ravenous," recalled a patient. This challenge is compounded if users have not established lasting lifestyle or habit modifications during treatment. Growing Interest Survey data show that millions of adults in the UK have used these injections in the past year, with interest remaining high. Use is more common among females than males. The 40s and 50s demographic shows the greatest level of interest. Many obtain the medications through private healthcare rather than the NHS. Finally, clinicians emphasize that while these medications are powerful agents for weight loss, they are not a permanent cure and lasting health benefits hinges on combined behavioural support.